The Procter & Gamble Company · PG · FY2026 Q3 · Calendar Q2 2026

PG Q3 FY26: Organic Sales Top 3% Across All Categories, $1B Cost Headwind Looms

P&G delivered a Q3 FY26 beat with EPS of $1.59 versus $1.56 estimated and revenue of $21.24B versus $20.53B estimated, as organic sales grew over 3% across all ten categories and seven regions. However, roughly $1 billion in after-tax cost headwinds from commodity, energy, and logistics pressures linked to Middle East geopolitical disruption are pressing margins. Management maintained FY26 guidance but now expects full-year EPS toward the lower end of the $6.83-$7.09 range. The stock saw a modest +0.92% abnormal return on the report day but drifted approximately 2.5% lower over the subsequent period, suggesting the market tempered its initial reception as the cost-pressure caveat sank in. At $148.66, the stock trades about 7% below the analyst consensus target of $159.75.

Reported Before market openNYSEConsumer Defensive $346.16B market cap
100quality score

Company context

Snapshot as of publication

The Procter & Gamble Company, commonly referred to as P&G, is a global enterprise that supplies a broad spectrum of branded consumer products to markets worldwide. The company's operations are divided into five main business divisions: Beauty; Grooming; Health Care; Fabric & Home Care; and Baby, Feminine & Family Care. The Beauty segment offers an assortment of hair care products, including conditioners, shampoos, styling aids, and treatments, under popular names like Head & Shoulders, Herbal Essences, Pantene, and Rejoice. It also features antiperspirants, deodorants, personal cleansing solutions, and skin care items from brands such as Olay, Old Spice, Safeguard, Secret, and SK-II. Within the Grooming division, P&G provides a range of shave care products and grooming appliances, prominently featuring brands like Braun, Gillette, and Venus. The Health Care unit encompasses oral hygiene essentials, including toothbrushes, toothpastes, and other dental care products sold under the Crest and Oral-B brand names.…

Earnings scorecard

Reported versus consensus
Reported EPS $1.59 Consensus $2
EPS surprise +1.9% Reported versus consensus
Reported revenue $21.23B Consensus $20.53B
Revenue surprise +3.4% Reported versus consensus

Earnings History

Estimate Beat Miss Match
PG REVENUE earnings history estimate and actual scatter chart 8 reported fiscal quarters and 4 future estimate-only quarters. Q2 '24 estimate $21B Q2 '24 actual $21B, miss Q3 '24 estimate $20B Q3 '24 actual $20B, miss Q4 '24 estimate $21B Q4 '24 actual $21B, miss Q1 '25 estimate $22B Q1 '25 actual $22B, miss Q4 '25 estimate $21B Q4 '25 actual $21B, beat Q1 '26 estimate $22B Q1 '26 actual $22B, beat Q2 '26 estimate $22B Q2 '26 actual $22B, miss Q3 '26 estimate $21B Q3 '26 actual $21B, beat Q4 '26 estimate $21B Q1 '27 estimate $23B Q2 '27 estimate $23B Q3 '27 estimate $22B

Analyst Consensus ?

ConsensusBuy50 ratings
Bullish2652.0%
Neutral2346.0%
Bearish12.0%

1 unmapped firm rating excluded from the percentages.

Analyst 52W Price Targets

$148.63Previous close
$40Low
$161.03Average
$192High

Latest persisted target per named analyst; persisted previous close from FN2's market snapshot as of Jul 28, 2026. Not an FN2 forecast.

Firm-level rating actions

FMP grade actions identify the grading firm, not a named analyst.

FirmRatingPrior ratingActionDate
Barclays Equal Weight Equal WeightMaintainJul 21, 2026
JP Morgan Overweight OverweightMaintainJul 16, 2026
B of A Securities Buy BuyMaintainJul 10, 2026
Wells Fargo Overweight OverweightMaintainApr 27, 2026
UBS Buy BuyMaintainApr 27, 2026
TD Cowen Hold HoldMaintainApr 27, 2026
Evercore ISI Group In Line In LineMaintainApr 27, 2026
Piper Sandler Neutral NeutralMaintainApr 8, 2026
Show 43 more rating actions

Named analyst price targets

Upside is calculated against the persisted previous close $148.63. FMP does not supply a rating on these named-analyst rows.

FirmAnalyst52W targetPrice when postedUpsideDate
BarclaysAnalyst unavailable$152$149.14 +2.3%Jul 21, 2026
BernsteinAnalyst unavailable$156$148.32 +5.0%Jun 11, 2026
UBSAnalyst unavailable$172$148.46 +15.7%Apr 27, 2026
Deutsche BankSteve Powers$163$148.63 +9.7%Apr 27, 2026
Evercore ISIRobert Ottenstein$162$148.11 +9.0%Apr 27, 2026
Wells FargoAnalyst unavailable$164$148.11 +10.3%Apr 27, 2026
BarclaysAnalyst unavailable$146$143.86 -1.8%Apr 14, 2026
RBC CapitalAnalyst unavailable$167$146.66 +12.4%Apr 9, 2026
Piper SandlerAnalyst unavailable$142$144.9 -4.5%Apr 8, 2026
Wells FargoAnalyst unavailable$177$160.07 +19.1%Feb 17, 2026
See 69 more

Track every rating change on PG the moment it posts. Free to start.

Start free

Market reaction

prior-close to event-session close
Stock move +1.7% Event window
SPY move +0.8% Same window
Abnormal move +0.9% Stock minus SPY
Volume 1.6× Versus trailing sessions
Subsequent drift -2.5% Up to 20 sessions
PGSPY benchmark

Follow PG with an agent that reads every filing, transcript, and price print. Free to start.

Try FN2 free

Transcript intelligence

What changed

Compared to Q2 FY26, described as the softest quarter due to inventory and trade headwinds, Q3 showed improvement with broad-based organic growth across every category and region. The $1 billion after-tax cost headwind was newly quantified this quarter, attributed to Middle East geopolitical disruption affecting commodity, energy, and logistics costs. Management introduced specific restructuring details: a 15% non-manufacturing headcount reduction target over two years and Supply Chain 3.0 automation rollout across nine categories. Innovation emphasis shifted toward home care (Dawn Powerwash, Fairy Skip the Soak, Mr. Clean) and beauty (SK-II, Pantene), whereas Q2 emphasized baby care (Pampers Prestige) and laundry (Tide Evo, Downy Intense). FY26 guidance was maintained in both quarters, but Q3 added the caveat that EPS is expected toward the lower end of the range, a subtle but meaningful shift in tone.

Guidance delta

FY26 guidance was maintained for the second consecutive quarter: organic sales growth of approximately +4%, core EPS of $6.83-$7.09, free-cash-flow productivity of 85-90%, and $15 billion in total cash returns to shareholders. The key delta is that management now expects full-year EPS to land toward the lower end of the range, reflecting the approximately $1 billion after-tax cost pressure from commodities, energy, and logistics. The 3% dividend increase and share repurchase program remain unchanged. Capex outlook continues to be increasing, consistent with the prior quarter's $10 billion capacity-investment plan.

Key takeaways

  • EPS of $1.59 beat the $1.56 estimate by 1.9%; revenue of $21.24B beat the $20.53B estimate by 3.4%.
  • Organic sales grew over 3% YoY with all ten categories and all seven regions posting growth.
  • Approximately $1 billion in after-tax cost headwinds from commodity, energy, and logistics pressures linked to Middle East conflict were quantified.
  • FY26 guidance was maintained, but full-year EPS is now expected toward the lower end of the $6.83-$7.09 range.
  • Dividend increased 3% and the $15 billion cash return plan remains unchanged.
  • Management flagged a 15% non-manufacturing headcount reduction target over two years alongside Supply Chain 3.0 automation across nine categories.

Management priorities

  • Scale up innovation pipeline across Baby Care (US), Tide Evo, and Pantene (Germany)
  • Roll out Supply Chain 3.0 automation technologies globally across nine categories
  • Invest in integrated data and AI tools for faster consumer-driven product development
  • Continue capacity additions in key categories under the $10 billion capex plan
  • Maintain dividend growth and share repurchase program targeting $15 billion in cash returns for FY26
  • Execute the 15% non-manufacturing headcount reduction over two years

Related earnings events

Consumer Defensive

Sources

  1. Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
  2. FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
  3. Polygon adjusted daily market bars · 2026-07-28T09:11:19.274761+00:00
  4. Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-07-28T09:11:19.271950+00:00

Methodology

Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.

Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.

Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.

By FN2 Research · Updated . For educational purposes only; not investment advice.